PD-1 x IL-15/IL-15Rα complex

Class

PD-1-targeted immunocytokine (anti-PD-1 antibody fused to an IL-15/IL-15Rα complex)

Pathway

PD-1 immune checkpoint blockade combined with tumor-microenvironment-targeted IL-15-mediated proliferation/activation of CD8+ T cells and NK cells

This mechanism combines two complementary strategies for stimulating the immune system against cancer. PD-1 is a checkpoint receptor on T cells that, when engaged by its ligands, dampens T-cell activity, a brake that tumors often exploit to evade attack. Blocking PD-1 releases this brake. IL-15 is a cytokine that drives proliferation and activation of cytotoxic CD8+ T cells and natural killer (NK) cells, the immune cells most responsible for killing tumor cells directly. By fusing an anti-PD-1 antibody to an IL-15/IL-15Rα complex, the molecule is designed to deliver cytokine stimulation preferentially to PD-1-expressing, often exhausted, T cells within the tumor microenvironment, while simultaneously blocking the inhibitory signal. The rationale is that checkpoint blockade alone frequently fails when T cells are too depleted or dysfunctional to respond, whereas an added proliferative and activating signal may restore their functional capacity. This class of engineered biologic is relevant across solid and hematologic cancers where T-cell exhaustion and immune evasion limit the effectiveness of checkpoint inhibition alone, and where broader, untargeted cytokine therapy has historically been limited by systemic toxicity.